GÖRG advises Heidelberg Pharma AG on a capital increase with gross proceeds of EUR 14.4 million

Munich, 30.04.2020

GÖRG advises Heidelberg Pharma AG on a capital increase with gross proceeds of EUR 14.4 million
GÖRG Partnerschaft von Rechtsanwälten mbB advised Heidelberg Pharma AG on a capital increase with gross proceeds of EUR 14.4 million under the leadership of Munich partner Dr. Bernt Paudtke.

The capital increase based on resolutions of 27 April 2020 represents approximately 10% of the company’s out-standing share capital and will increase the total number of shares to 31,030,572. The 2,820,961 new shares were placed exclusively with the major shareholder dievini Hopp Biotech holding GmbH & Co. KG, Walldorf and institutional investors via an accelerated book building transaction and will be admitted to trading on the Frankfurt Stock Exchange. The issue price was EUR 5.10 per share, resulting in gross proceeds of EUR 14.4 million for Heidelberg Pharma AG.

The capital increase has been executed by MainFirst Bank AG acting as global coordinator and sole bookrunner.

Advisors Heidelberg Pharma

GÖRG Partnerschaft von Rechtsanwälten mbB
Dr. Bernt Paudtke, Partner, M&A / Corporate, Munich
Dr. Christian Glauer, Associated Partner, M&A / Corporate, Munich
Tobias Reichenberger, Associate, M&A / Corporate, Munich

Legal Department Heidelberg Pharma AG
Mikaela Dimitropoulos (Director Legal, HR & IP)   

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6.


 Newsletter Icon

We inform you about current legal developments in the areas relevant to you.

Subscribe to our Newsletter


Einige der von uns gesetzten Cookies dienen dazu, bestimmte Funktionen unserer Webseiten zu ermöglichen, insbesondere zur Steuerung des Cookie-Banners (damit dieses bei Ihren erneuten Besuchen nicht immer wieder angezeigt wird). Diese Cookies enthalten keine personenbezogenen Daten, insbesondere nicht Ihre IP-Adresse. Andere Cookies, die zu Analysezwecken gesetzt werden (siehe hierzu auch den Abschnitt „Web-Analyse-Tools“), helfen uns zu verstehen, wie Besucher mit unseren Webseiten interagieren. Diese Cookies dienen dazu, die Nutzung unserer Webseiten statistisch zu erfassen und zum Zwecke der Optimierung unseres Angebotes auszuwerten. Die Analyse-Cookies werden bis zu 13 Monate gespeichert.

Save Cancel OK Deny tracking Privacy policy